Please login to the form below

Not currently logged in
Email:
Password:

ASH: Pradaxa antidote effective in key patient groups

Boehringer posts positive data on use of idarucizumab in elderly and people with kidney impairment
Boehringer Pradaxa dabigatran antidote

An antidote to Boehringer Ingelheim's oral anticoagulant Pradaxa has demonstrated its effectiveness in two key patient groups.

According to data presented at this week's American Society of Hematology (ASH) meeting in San Francisco, a five-minute infusion of idarucizumab was able to reverse the blood thinning effects of Pradaxa (dabigatran) in elderly patients and in patients with mild or moderate kidney impairment.

The data follows previous clinical trials that have demonstrated the ability of idarucizumab to reverse the effects of Pradaxa in younger, healthy male volunteers

Dr Georg van Husen, head of Boehringer's cardiovascular business, said: “These latest data are important because this study included volunteers who were older and who had impaired kidney function – characteristics that are common among patients who require anticoagulation.

“The growing evidence supports idarucizumab as a highly targeted antidote for dabigatran which can provide immediate, complete and sustained reversal.”

Pradaxa is one of several new oral anticoagulants that have revolutionised the treatment and prevention of blood clots in recent years, providing a far more convenient option than older injectable treatments such as warfarin and heparin.

However, despite their inconvenience, the older treatments have effective antidotes if the anticoagulation effect needs to be reversed – something that the newer drugs lack, leading to concerns over their safety.

Pradaxa is doing well for Boehringer despite these concerns, taking in €1.2bn for the 12-month period ending March 2014.

An antidote could push sales further, however, giving the drug an edge over its close rivals Eliquis (apixaban), from Bristol-Myers Squibb and Pfizer, and Bayer's Xarelto (rivaroxaban).

9th December 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics